跳至主要内容
临床试验/NCT06421103
NCT06421103招募中不适用

Investigating Micro-dosing of Indocyanine Green (ICG) for Intraoperative Perfusion Assessment in Children.

Great Ormond Street Hospital for Children NHS Foundation Trust1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年6月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
90
试验地点
1
主要终点
Minimum clinically useful dose of ICG in children

研究概览

简要总结

The goal of this cohort study is to identify the lowest dose of Indocyanine Green (ICG) that achieves satisfactory intra-operative fluorescence for the assessment of gastrointestinal or genitourinary tract perfusion in children.

详细描述

Indocyanine Green (ICG) fluorescence-guided surgery (FGS) can be used to assess gastrointestinal and genitourinary tract perfusion intra-operatively. In adults, the use of ICG has been shown to improve surgical outcomes. ICG is safely used intra-operatively in children, but there is a lack of evidence regarding the lowest clinically useful dose of ICG.

This is a single centre open-label dose escalation study that aims to:

  1. identify the minimal clinically useful dose of ICG for intra-operative perfusion assessment in children (0 - 18 years old)
  2. assess the safety profile of intra-operative ICG in children
  3. characterise the intra-operative fluorescence of ICG in children

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
— 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Children aged ≤18 years of age
  • Elective surgery including gastrointestinal or genitourinary tract perfusion assessment

排除标准

  • Renal and liver dysfunction
  • Active infection
  • Coagulopathy
  • Complex congenital heart defect
  • Previous documented allergy to ICG injection or other iodinated contrast agents
  • Patients suffering from hyperthyroidism or autonomic thyroid adenomas
  • Premature infants or neonates in whom exchange transfusion is indicated, due to the hyperbilirubinaemia risk
  • Concurrent use of sodium bisulphite-containing preparations, such as certain heparin preparations

研究组 & 干预措施

Micro-dosing Indocyanine Green (ICG)

Experimental

Multiple dose levels of intravenous Indocyanine Green (ICG) administered intra-operatively. Starting dose will be 10% of standard (for the study institution) and escalated as per protocol.

干预措施: Indocyanine Green (ICG) (Drug)

结局指标

主要结局

Minimum clinically useful dose of ICG in children

时间窗: 60 minutes (intra-operative)

Identify the minimum dose of ICG at which intra-operative perfusion assessment is achieveable. Assessment will be based objectively on mean fluorescence intensity and the fluorescence-time curve, and subjectively by the operating surgeon.

Number of adverse drug events at each dose level

时间窗: 30 days

An appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product

次要结局

  • Surgical complications(30 days)
  • Post-operative morbidity(90 days)
  • Length of stay(90 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验